B
11.97
0.06 (0.55%)
| Previous Close | 11.90 |
| Open | 11.81 |
| Volume | 97,363 |
| Avg. Volume (3M) | 506,341 |
| Market Cap | 652,843,904 |
| Price / Book | 1.50 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Bicara Therapeutics Inc. | Bullish | - |
AIStockmoo Score
1.9
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Red Tree Management, Llc | 30 Jun 2025 | 3,170,509 |
| Tpg Gp A, Llc | 30 Jun 2025 | 3,010,425 |
| Blackstone Inc. | 30 Jun 2025 | 1,224,336 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 234.31%) | Buy |
| Median | 38.00 (217.59%) | |
| Low | 36.00 (Piper Sandler, 200.88%) | Buy |
| Average | 38.00 (217.59%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 11.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Aug 2025 | 40.00 (234.31%) | Buy | 11.84 |
| Piper Sandler | 19 Aug 2025 | 36.00 (200.88%) | Buy | 11.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Bicara Therapeutics to Participate in Upcoming Investor Conferences |
| 12 Aug 2025 | Announcement | Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |